Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ajinomoto Co. Inc.

www.ajinomoto.com

Latest From Ajinomoto Co. Inc.

Albireo Making Headway In Rare Pediatric Liver Diseases With IBAT Inhibition

Biotech hopes to launch a Phase III trial in the rare disorder PFIC before year’s end. It thinks its therapy could offer similar benefits to surgery in reducing pruritus and improving liver parameters.

Rare Diseases Clinical Trials

Synthetic Biology And The Computerization Of Drug Development

Synthetic biology offers opportunity across many industries, but the ultimate prize may be health care. The millions of dollars investors have poured into companies developing CAR-T cell therapies and gene editing technologies points to growing confidence in the power of gene manipulation to generate novel, approvable therapeutics, even if for now these are just the early steps toward creating fully synthetic organisms.

BioPharmaceutical Innovation

Eisai Steps Well ‘Beyond The Pill’ In New Japan Care Service

Japanese major Eisai is working with a communications company for a new online system in Japan that will more closely link chronic disease patients and medical care providers, with a number of expected benefits including treatment compliance that could potentially help stem sales declines for two mainstay products.

Commercial Companies

Japan Venture Taps ‘Deep Learning’ To Improve Drug Discovery

The Japanese peptide venture Interprotein is tapping into artificial intelligence technology with the hope of improving the efficiency and accuracy of its drug discovery efforts.

BioPharmaceutical Asia Pacific
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register